Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 207-215 , December 2008

Liver-Directed Therapies for Colorectal Metastases

  • Keith Stuart, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Keith Stuart, MD, Chairman, Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington, MA 01805

References 

  1. Gilbert HA. Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss  editors. Fundamental Aspects of Metastasis. 1976;p. 385–405Amsterdam, North-Holland
  2. Myers JD. The hepatic blood flow in Laennec's cirrhosis, with an estimate of the relative contributions from portal vein and hepatic artery. J Clin Invest. 1950;29(6):836–837
  3. Lautt WW. Hepatic vasculature: a conceptual review. Gastroenterology. 1977;73(5):1163–1169
  4. Lautt WW. The 1995 Ciba-Geigy Award Lecture (Intrinsic regulation of hepatic blood flow). Can J Physiol Pharmacol. 1996;74(3):223–233
  5. Ginsberg M, Grayson J. Contributions to liver blood flow of the portal vein and hepatic artery. J Physiol. 1952;118(2):16
  6. Grayson J, Mendel D. Observations on the intrahepatic flow interactions of the hepatic artery and portal vein. J Physiol. 1957;139(2):167–177
  7. Ackerman NB, et al. The blood supply of experimental liver metastases (I. The distribution of hepatic artery and portal vein blood to “small” and “large” tumors). Surgery. 1969;66(6):1067–1072
  8. Ackerman NB, Lien WM, Silverman NA. The blood supply of experimental liver metastases (3. The effects of acute ligation of the hepatic artery or portal vein). Surgery. 1972;71(4):636–641
  9. Laufman LR, et al. Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer. J Clin Oncol. 1984;2(12):1382–1389
  10. Taylor I, Bennett R, Sherriff S. The blood supply of colorectal liver metastases. Br J Cancer. 1978;38(6):749–756
  11. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–977
  12. Lien WM, Ackerman NB. The blood supply of experimental liver metastases (II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber). Surgery. 1970;68(2):334–340
  13. Ridge JA, et al. Perfusion of colorectal hepatic metastases (Relative distribution of flow from the hepatic artery and portal vein). Cancer. 1987;59(9):1547–1553
  14. Sigurdson ER, et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5(11):1836–1840
  15. Zike WL, Safaie-Shirazi S, Gulesserian HP. Hepatic artery ligation and cytotoxic infusion in treatment of liver neoplasms. Arch Surg. 1975;110(5):641–643
  16. Almersjo O, et al. Hepatic artery ligation as pretreatment for liver resection of metastatic cancer. Rev Surg. 1966;23(5):377–380
  17. Mori W, Masuda M, Miyanaga T. Hepatic artery ligation and tumor necrosis in the liver. Surgery. 1966;59(3):359–363
  18. Nilsson LA. Therapeutic hepatic artery ligation in patients with secondary liver tumors. Rev Surg. 1966;23(5):374–376
  19. Murray-Lyon IM, et al. Treatment of secondary hepatic tumors by ligation of the hepatic artery and perfusion of the portal vein with cytoxic drugs. Gut 1969. 1969;10(12):1057–1058
  20. Madding GF, Kennedy PA, Sogemeier E. Hepatic artery ligation for metastatic tumor in the liver. Am J Surg. 1970;120(1):95–96
  21. Murray-Lyon IM, et al. Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet. 1970;2(7665):172–175
  22. Gulesserian HP, Lawton RL, Condon RE. Hepatic artery ligation and cytotoxic infusion in treatment of liver metastases. Arch Surg. 1972;105(2):280–285
  23. Murray-Lyon IM. Treatment of hepatic tumours by ligation of the hepatic artery and infusion of cytotoxic drugs. J R Coll Surg Edinb. 1972;17(3):156–161
  24. Fortner JG, et al. Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann Surg. 1973;178(2):162–172
  25. Cuschieri A, Swain C. Hepatic artery ligation and prolonged cytotoxic therapy in advanced primary and secondary liver tumours. Proc R Soc Med. 1975;68(11):678–680
  26. Ramming KP, et al. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg. 1976;132(2):236–242
  27. Evans JT. Hepatic artery ligation in hepatic metastases from colon and rectal malignancies. Dis Colon Rectum. 1979;22(6):370
  28. Karakousis CP, Douglass HO, Holyoke ED. Technique of infusion chemotherapy, ligation of the hepatic artery and dearterialization in malignant lesions of the liver. Surg Gynecol Obstet. 1979;149(3):403–407
  29. Carlsson G, Hafstrom L. The effect on extrahepatic cancer of hepatic artery ligation: an experimental study in rats with liver tumors. Cancer Lett. 1983;20(1):55–60
  30. Takagi H, et al. Ligation and catheterization of the hepatic artery for palliative treatment of malignant hepatic tumors. J Surg Oncol. 1983;23(4):219–222
  31. Al-Jurf AS, et al. Hepatic artery ligation and chemotherapeutic infusion in the treatment of hepatic malignancy. J Surg Oncol. 1984;27(2):119–123
  32. Petrelli NJ, et al. Hepatic artery ligation for liver metastasis in colorectal carcinoma. Cancer. 1984;53(6):1347–1353
  33. Yang R, et al. Experimental liver cancer: improved response after hepatic artery ligation and infusion of tumor necrosis factor-alpha and interferon-gamma. Surgery. 1995;118(4):768–772discussion 772-774
  34. Bengmark S, Jeppsson B. Permanent hepatic artery ligation versus temporary dearterialization in the treatment of hepatic tumors. Recent Results Cancer Res. 1986;100:268–275
  35. Gerard A, Pector JC, Bleiberg H. Hepatic artery ligation or embolization and locoregional chemotherapy of liver metastases from colorectal cancer. Gan To Kagaku Ryoho. 1988;15(8 Pt. 2):2351–2354
  36. Gerard A, et al. Hepatic artery ligation with and without portal infusion of 5-FU (A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group)). Eur J Surg Oncol. 1991;17(3):289–294
  37. Naredi P, et al. A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. Eur J Surg Oncol. 2003;29(5):459–466
  38. Butler JA, et al. Hepatic artery versus portal vein and systemic infusion of fluorodeoxyuridine of rabbit VX-2 hepatic implants. Am J Surg. 1989;157(1):126–129
  39. Daly JM, et al. Regional infusion for colorectal hepatic metastases (A randomized trial comparing the hepatic artery with the portal vein). Arch Surg. 1987;122(11):1273–1277
  40. Balch CM, Urist MM. Intraarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res. 1986;100:234–247
  41. Ekberg H, et al. Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis. J Surg Oncol. 1986;31(4):246–254
  42. Hohn DC, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7(11):1646–1654
  43. Rougier P. Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? (The case of liver metastases from colorectal cancer). Recent Results Cancer Res. 1998;147:3–12
  44. Fiorentini G, et al. Locoregional therapy for liver metastases from colorectal cancer: the possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. Hepatogastroenterology. 2001;48(38):305–312
  45. Valeri A, et al. Intra-arterial hepatic chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. Anticancer Res. 1994;14(5B):2215–2219
  46. Cyjon A, et al. Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy. Br J Cancer. 2001;85(4):504–508
  47. Fazio N, et al. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. Anticancer Res. 2003;23(6D):5023–5030
  48. Heinrich S, et al. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery. 2003;133(1):40–48
  49. Kemeny N. Review of regional therapy of liver metastases in colorectal cancer. Semin Oncol. 1992;19(2 suppl 3):155–162
  50. Kemeny N, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12(11):2288–2295
  51. Kemeny N, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma (New dose schedules and survival update). Cancer. 1994;73(4):1134–1142
  52. Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol. 1999;26(5):524–535
  53. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 2003;8(6):553–566
  54. Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–1403
  55. Lorenz M, et al. Temporary chemoembolization of colorectal liver metastases with degradable starch microspheres. Eur J Surg Oncol. 1989;15(5):453–462
  56. Borner M, et al. Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol. 1992;3(2):113–115
  57. Kameyama M, et al. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery. 1993;114(1):97–101
  58. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology. 1993;189(2):417–422
  59. Martinelli DJ, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer. 1994;74(6):1706–1712
  60. Sanz-Altamira PM, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997;40(7):770–775
  61. Tellez C, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998;82(7):1250–1259
  62. Patel NH, Jindal RM. The role of chemoembolization in the treatment of colorectal hepatic metastases. Hepatogastroenterology. 2001;48(38):448–452
  63. Danesi R, Di Paolo A. Chemoembolization is effective as second-line therapy in patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer. 2002;2(3):180–181
  64. Popov I, et al. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit. Neoplasma. 2002;49(1):43–48
  65. Vogl TJ, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025–1034
  66. Weidmann B, et al. Treatment of a cystic liver metastasis by intralesional injection of mitomycin C. Ann Oncol. 1991;2(10):769–770
  67. Hoye RC, et al. Effects of neodymium laser on normal liver and Vx2 carcinoma transplanted into the liver of experimental animals. J Natl Cancer Inst. 1968;41(5):1071–1082
  68. Hahl J, et al. Laser-induced hyperthermia in the treatment of liver tumors. Lasers Surg Med. 1990;10(4):319–321
  69. Van Hillegersberg R, et al. Treatment of experimental liver metastases with a noncontact neodymium: YAG laser. J Surg Res. 1992;53(2):128–135
  70. Vogl TJ, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. Radiology. 1995;196(1):257–265
  71. Germer C, et al. Laser-induced thermotherapy for the treatment of liver metastasis (Correlation of gadolinium-DTPA-enhanced MRI with histomorphologic findings to determine criteria for follow-up monitoring). Surg Endosc. 1998;12(11):1317–1325
  72. Usatoff V, Habib NA. Update of laser-induced thermotherapy for liver tumors. Hepatogastroenterology. 2001;48(38):330–332
  73. Izzo F. Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors. Ann Surg Oncol. 2003;10(5):491–497
  74. Nikfarjam M, Christophi C. Interstitial laser thermotherapy for liver tumours. Br J Surg. 2003;90(9):1033–1047
  75. Becker D, et al. Percutaneous ethanol injection and radio-frequency ablation for the treatment of nonresectable colorectal liver metastases—techniques and results. Langenbecks Arch Surg. 1999;384(4):339–343
  76. Virag J, et al. Experiences with ethanol infiltration of the liver metastases of colorectal tumors (preliminary study). Acta Chir Hung. 1997;36(1-4):386–388
  77. Vogl TJ, et al. CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours. Br J Cancer. 2002;86(4):524–529
  78. Livraghi T, et al. Fine needle percutaneous intratumoral chemotherapy under ultrasound guidance: a feasibility study. Tumori. 1986;72(1):81–87
  79. Brincker H. Direct intratumoral chemotherapy. Crit Rev Oncol Hematol. 1993;15(2):91–98
  80. Goldberg EP, et al. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol. 2002;54(2):159–180
  81. Ravikumar TS, et al. Experimental and clinical observations on hepatic cryosurgery for colorectal metastases. Cancer Res. 1991;51(23 Pt. 1):6323–6327
  82. Weaver ML, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer. 1995;76(2):210–214
  83. Redlich PN, et al. Surgical management of colorectal metastases to the liver: role of resection and cryosurgery. Wis Med J. 1996;95(12):859–863
  84. Tandan VR, Harmantas A, Gallinger S. Long-term survival after hepatic cryosurgery versus surgical resection for metastatic colorectal carcinoma: a critical review of the literature. Can J Surg. 1997;40(3):175–181
  85. Ruers TJ, Jager GJ, Wobbes T. Cryosurgery for colorectal liver metastases. Semin Oncol. 2000;27(5 suppl 10):120–125
  86. Neeleman N, et al. Cryosurgery as treatment modality for colorectal liver metastases. Hepatogastroenterology. 2001;48(38):325–329
  87. Ruers TJ, et al. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg. 2001;88(6):844–849
  88. Xu KC, et al. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol. 2008;14(9):1430–1436
  89. Bageacu S, et al. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(5):590–596
  90. Ravikumar TS, Sotomayor R, Goel R. Cryosurgery in the treatment of liver metastasis from colorectal cancer. J Gastrointest Surg. 1997;1(5):426–432
  91. King J, et al. Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg. 2004;91(2):217–223
  92. Kainuma O, et al. Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Hepatogastroenterology. 1999;46(26):1071–1077
  93. Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut. 2002;50(1):1–5
  94. Stippel DL, et al. Intraoperative radiofrequency ablation using a 3D navigation tool for treatment of colorectal liver metastases. Onkologie. 2002;25(4):346–350
  95. Cheng J, et al. Laparoscopic radiofrequency ablation and hepatic artery infusion pump placement in the evolving treatment of colorectal hepatic metastases. Surg Endosc. 2003;17(1):61–67
  96. Lau TN, Lo RH, Tan BS. Colorectal hepatic metastases: role of radiofrequency ablation. Ann Acad Med Singapore. 2003;32(2):212–218
  97. Majeed AW. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases (Br J Surg 2003;90:1240-1243). Br J Surg. 2003;90(12):1611
  98. Oshowo A, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90(10):1240–1243
  99. Abdalla EK, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–825discussion 825-827
  100. Basdanis G, et al. Clinical short-term results of radiofrequency ablation in patients with liver metastases from colorectal cancer. Tech Coloproctol. 2004;1(suppl 8):s187–s189
  101. Berber E, et al. Laparoscopic radiofrequency ablation of liver tumors combined with colorectal procedures. Surg Laparosc Endosc Percutan Tech. 2004;14(4):186–190
  102. Lencioni R, et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol. 2004;39(11):689–697
  103. Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going?. J Clin Oncol. 2005;23(7):1342–1347
  104. Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma. Cancer Control. 2006;13(1):48–51
  105. Park IJ, et al. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol. 2008;15(1):227–232
  106. Nikfarjam M, et al. The apoptotic response of liver and colorectal liver metastases to focal hyperthermic injury. Anticancer Res. 2005;25(2B):1413–1419
  107. Mala T, et al. Cryoablation of colorectal liver metastases: minimally invasive tumour control. Scand J Gastroenterol. 2004;39(6):571–578
  108. Joosten J, et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol. 2005;31(10):1152–1159
  109. Mala T, et al. Percutaneous cryoablation of colorectal liver metastases: potentiated by two consecutive freeze-thaw cycles. Cryobiology. 2003;46(1):99–102
  110. Yan TD, Nunn DR, Morris DL. Recurrence after complete cryoablation of colorectal liver metastases: analysis of prognostic features. Am Surg. 2006;72(5):382–390
  111. Cady B, Oberfield RA. Arterial infusion chemotherapy of hepatoma. Surg Gynecol Obstet. 1974;138(3):381–384
  112. Clouse ME, et al. Complications of long term transbrachial hepatic arterial infusion chemotherapy. AJR Am J Roentgenol. 1977;129(5):799–803
  113. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer (Meta-Analysis Group in Cancer). J Natl Cancer Inst. 1996;88(5):252–258
  114. Bern MM, et al. Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer. 1978;42(2):399–405
  115. Ramming KP. The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors. Semin Oncol. 1983;10(2):199–205
  116. Shepherd FA, et al. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol. 1987;5(4):635–640
  117. Ansfield FJ, et al. Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer. 1975;36(suppl 6):2413–2417
  118. Campbell KA, et al. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol. 1993;11(5):822–826
  119. Patt YZ, Mavligit GM. Arterial chemotherapy in the management of colorectal cancer: an overview. Semin Oncol. 1991;18(5):478–490
  120. Fordy C, et al. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer. 1998;78(8):1058–1060
  121. Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer. 2005;5(3):166–174
  122. Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57–65
  123. Durand-Zaleski I, et al. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer. 1998;83(5):882–888
  124. Kerr DJ, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361(9355):368–373
  125. Mocellin S, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol. 2007;25(35):5649–5654
  126. Neyns B, et al. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res. 2006;26(1B):611–619
  127. Del Freo A, et al. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo. 2006;20(6A):743–746
  128. Ducreux M, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881–4887
  129. Boige V, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–226
  130. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23(9):2038–2048
  131. Xu J, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg. 2007;245(4):583–590
  132. Wang P, et al. Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials. World J Gastroenterol. 2005;11(25):3817–3822
  133. Clancy TE, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg. 2005;9(2):198–206
  134. Nelson RL, Freels S. A systematic review of hepatic artery chemotherapy after hepatic resection of colorectal cancer metastatic to the liver. Dis Colon Rectum. 2004;47(5):739–745
  135. Kemeny N, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–2048
  136. Yamaguchi A, et al. Correlation between angiographically assessed vascularity and blood flow in hepatic metastases in patients with colorectal carcinoma. Cancer. 2000;89(6):1236–1244
  137. Shankar A, Loizidou M, Taylor I. The vascularity of colorectal liver metastases. Eur J Surg Oncol. 1996;22(4):389–396
  138. Tritos NA, Stuart K, Hartzband PI. Hypothyroidism in two patients after hepatic arterial chemoembolization. Ann Intern Med. 2001;134(6):535
  139. Salman HS, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer. 2002;2(3):173–179
  140. Hunt TM, et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg. 1990;77(7):779–782
  141. Voigt W, et al. A new chemoembolization protocol in refractory liver metastasis of colorectal cancer—a feasibility study. Onkologie. 2002;25(2):158–164
  142. Abramson RG, et al. Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy. Radiology. 2000;216(2):485–491
  143. Leichman CG, et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial. Cancer. 1999;86(5):775–781
  144. You YT, et al. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis. 2006;21(1):33–37
  145. Trerotola SO. Science to practice: can combination therapy for colorectal liver metastases improve results over chemoembolization or ablation alone?. Radiology. 2005;237(2):381–382
  146. Varela M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481
  147. Taylor RR, et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30(1):7–14
  148. Tang Y, et al. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. J Control Release. 2008;127(1):70–78
  149. Eyol E, et al. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis. 2008;25(3):273–282
  150. Aliberti C, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26(5B):3793–3795
  151. Fiorentini G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007;21(6):1085–1091
  152. Tang Y, et al. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release. 2006;116(2):e55–e56
  153. Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg. 2007;142(7):675–682
  154. Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583–592
  155. Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–1563
  156. Denecke T, et al. Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol. 2008;18(5):892–902
  157. Ng SS, et al. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig Dis Sci. 2008;
  158. Neff R, et al. The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest. 2008;26(2):173–177
  159. Lim L, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35(4):222–227
  160. Sato KT, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology. 2008;247(2):507–515
  161. Rowe BP, et al. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. Conn Med. 2007;71(9):523–528
  162. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. Aust NZ J Surg. 2006;76(8):696–703
  163. Szyszko T, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28(1):15–20
  164. Sharma RA, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–1106
  165. Murthy R, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18(12):1588–1591
  166. Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging. 2005;30(4):419–426
  167. Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol. 2007;48(3):253–258
  168. Suppiah A, et al. Long-term results of percutaneous radiofrequency ablation of unresectable colorectal hepatic metastases: final outcomes. Dig Surg. 2007;24(5):358–360
  169. Siperstein AE, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–565discussion 565-567
  170. Jakobs TF, et al. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res. 2006;26(1B):671–680
  171. Mulier S, et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol. 2008;15(1):144–157
  172. Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol. 2008;15(1):11–13
  173. McGrane S, McSweeney SE, Maher MM. Which patients will benefit from percutaneous radiofrequency ablation of colorectal liver metastases? (Critically appraised topic). Abdom Imaging. 2008;33(1):48–53
  174. Bremers AJ, Ruers TJ. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. Eur J Surg Oncol. 2007;33(6):752–756
  175. White RR, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg. 2007;11(3):256–263
  176. Fahy BN, Jarnagin WR. Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. Surg Clin North Am. 2006;86(4):1005–1022
  177. White TJ, et al. Percutaneous radiofrequency ablation of colorectal hepatic metastases—initial experience (An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases). Dig Surg. 2004;21(4):314–320
  178. Martin RC, Scoggins CR, McMasters KM. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. J Surg Oncol. 2006;93(5):387–393
  179. Yamagami T, et al. Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2005;16(4):549–554
  180. Scaife CL, et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003;10(4):348–354
  181. Evrard S, et al. Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. Gastroenterol Clin Biol. 2007;31(2):141–145
  182. Yan TD, Padang R, Morris DL. Long-term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: long-term survival can be achieved in patients with multiple bilateral liver metastases. J Am Coll Surg. 2006;202(1):100–111
  183. Rivoire M, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95(11):2283–2292
  184. Stubbs RS, Alwan MH, Booth MW. Hepatic cryotherapy and subsequent hepatic arterial chemotherapy for colorectal metastases to the liver. HPB Surg. 1998;11(2):97–104
  185. Maor MH, et al. Stereotactic radiosurgery for brain metastases: results and prognostic factors. Int J Cancer. 2000;90(3):157–162
  186. Stafinski T, et al. Effectiveness of stereotactic radiosurgery alone or in combination with whole brain radiotherapy compared to conventional surgery and/or whole brain radiotherapy for the treatment of one or more brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32(3):203–213
  187. Cesaretti JA, et al. Stereotactic radiosurgery for thoracic malignancies. Ann Thorac Surg. 2008;85(2):S785–S791
  188. Brown WT, et al. Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J. 2008;101(4):376–382
  189. Mendez Romero A, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol. 2006;45(7):831–837
  190. Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006;16(2):77–84
  191. Boda-Heggemann J, et al. Frameless stereotactic radiosurgery of a solitary liver metastasis using active breathing control and stereotactic ultrasound. Strahlenther Onkol. 2006;182(4):216–221
  192. Schefter TE, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–137816:1059-1065
  193. Shun SC, et al. Changes in quality of life and its related factors in liver cancer patients receiving stereotactic radiation therapy. Support Care Cancer. 2008;
  194. Fuss M, Thomas CR. Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors. Ann Surg Oncol. 2004;11(2):130–138
  195. Song DY, et al. Stereotactic body radiation therapy (Rationale, techniques, applications, and optimization). Oncology (Williston Park). 2004;18(11):1419d-1430; discussion 1430, 1432, 1435-1436
  196. Solberg TD, Kavanagh BD, Medin PM. Stereotactic body radiation therapy: a new paradigm in radiotherapy management of cancer. J Am Coll Radiol. 2008;5(5):673–677
  197. Timmerman RD, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947–952
  198. Hoyer M, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–830
  199. Ask A, Johansson B, Glimelius B. The potential of proton beam radiation therapy in gastrointestinal cancer. Acta Oncol. 2005;44(8):896–903
  200. Gedroyc WM, Anstee A. MR-guided focused ultrasound. Exp Rev Med Devices. 2007;4(4):539–547

PII: S1043-1489(08)00052-3

doi: 10.1053/j.scrs.2008.09.002

Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 207-215 , December 2008

Article Tools